CClinicalTrials.gg
CompletedNCT00966550TOMUpdated Mar 14, 2017Results posted

A Study of Tomato Products and Disease Risk

An interventional study of Tomato and Non-tomato in Inflammation, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-14.

Sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this research study is to test whether certain compounds in tomatoes will help reduce factors in the subject's blood associated with disease risk. The investigators want to know if the tomato-associated compounds will lower or improve the status of these factors, like cholesterol and inflammation. In this research study, the subject will be asked to consume high fat test meals on two separate occasions. The investigators want to see how the subject's body responds to a standard high fat meal, one meal with tomato products and one meal without tomato products. The investigators will measure the subject's blood throughout the study period to determine if consumption of tomato products reduces factors in their blood associated with disease risk.

Read the detailed description

This study will take three weeks at most, and require one initial screening visit lasting approximately 45 minutes and two study visits each lasting approximately 6 - 8 hours. The investigators are looking for healthy, non-smoking male and female volunteers between the ages of 18 - 65, with no medical history of diabetics, heart, lung, kidney, stomach, or liver disease.

The initial screening visit will determine subject' eligibility through height, weight and waist circumference measurements, blood glucose (finger prick) test and a fasting screening blood draw. There will be no compensation for the screening visit, other than transportation costs.

If subject qualify, subject will continue to the two study visits. Each visit will require subject to have blood drawn several times during subject' study visit (total amount of blood equal to approximately 1 ½ tablespoons). To make this process more tolerable, a registered nurse will place a catheter (similar to what happens when you give blood) into subject's vein for ease in drawing blood. After the catheter placement and the first blood draw, subject will be asked to eat the test meal (tomato or non-tomato meal) and then subject will continue to have blood taken at specific time points for the next 6 hours. The investigators will also do an ultrasound on subject's arm to measure blood flow both before eating and midway through the 6 - hour study visit. The investigators will ask that subject not consume tomatoes or tomato products during the course of the study and record all food and beverages consumed on certain days.

02

Conditions studied

  • Inflammation

Browse trials for

Keywords

  • Tomato
  • Nutrition
03

In context

Inflammation

3,439 studies on the registry are indexed under Inflammation; 629 are open to participants now.

This study's enrollment of 25 is below the median of 50 across 2,437 interventional studies indexed under Inflammation.

Browse Inflammation studies →

Lead sponsor

Clinical Nutrition Research Center, Illinois Institute of Technology is the lead sponsor of 59 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Male and female
  • Between ages of 18-65
  • BMI between 19 and 24 and hsCRP \< 1mg/L
  • BMI between 25 and 35 and hsCRP > 2.5mg/L
  • No clinical evidence of cardiovascular, respiratory, renal, GI or hepatic disease

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or lactating
  • allergies or intolerances to foods consumed in the study
  • fasting blood glucose > 110mg/dL
  • taking OTC antioxidant supplements, prescription meds that may interfere with study endpoints
  • unusual dietary habits
  • actively trying to lose or gain weight
  • addicted to drugs or alcohol
  • medically documented psychiatric or neurological disturbances
  • smoker (past smoker allowed if cessation > 2 years)
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Tomato

    Tomato with high carb/fat meal

    Other: Tomato

  • Placebo comparator
    Non-Tomato

    Non-tomato with high carb/fat meal

    Other: Non-tomato

Interventions

  • OtherTomato

    Tomato with high carb/fat meal

    Also known as: Active Comparator

  • OtherNon-tomato

    Non-tomato with high carb/fat meal

    Also known as: Placebo Comparator

06

What researchers measure

Primary outcomes

  1. IL-6 Concentrations

    Time frame: 6 hour postprandial study

07

Results

Posted Oct 16, 2014
Limitations and caveats
Acute study; Chronic effect should be investigated.

Participant flow

Participant flow — Overall Study
MilestoneTomato First Then Non-tomatoNon-tomato First Then Tomato
Started1312
Completed1312
Not completed00

Outcome measures

PrimaryIL-6 Concentrations
Time frame:
6 hour postprandial study
Reported as:
Least squares mean · pg/mL
IL-6 Concentrations
pg/mLTomatoNon-tomato
IL-6 Concentrations2.2 ± 0.272.6 ± 0.28
Statistical analysis
  • Tomato vs Non-tomato · Mixed Models Analysis · p = <0.0001

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tomato—0/25 (0%)0/25 (0%)
Non-tomato—0/25 (0%)0/25 (0%)

Baseline characteristics

A total of twenty five subjects completed the crossover study (n = 12 females, n = 13 males).

Age, Continuous
Age, Continuous(years)Tomato First Then Non-tomatoNon-tomato First Then TomatoTotal
Mean24.9 ± 528.7 ± 10.727 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)Tomato First Then Non-tomatoNon-tomato First Then TomatoTotal
Female8412
Male5813
08

Study locations

1 site
  • Clinical Nutrition Research Center
    Chicago, Illinois 60616, United States
09

References and documents

Publications

  • Burton-Freeman B, Talbot J, Park E, Krishnankutty S, Edirisinghe I. Protective activity of processed tomato products on postprandial oxidation and inflammation: a clinical trial in healthy weight men and women. Mol Nutr Food Res. 2012 Apr;56(4):622-31. doi: 10.1002/mnfr.201100649. Epub 2012 Feb 14. PubMed 22331646 ↗

Individual participant data

Plan to share: Undecided

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00966550
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Collaborators
Tomato Products Wellness Council
Responsible party
Sponsor
First posted
Aug 27, 2009
Start date
Aug 2009
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Oct 16, 2014
Last update
Mar 14, 2017

Study contacts

Britt Burton-Freeman, MS, PhD
principal investigator · Clinical Nutrition Research Center, Illinois Institute of Technology
Indika Edirisinghe, PhD
principal investigator · Clinical Nutrition Research Center, Illinois Institute of Technology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion